The 36-month CORE-VNS study findings showed sustained seizure reduction, improved quality of life, and reduced seizure-related hospitalizations among people with drug-resistant epilepsy receiving vagus nerve stimulation therapy.
|Slideshows|August 21, 2017
The Human Epilepsy Project
Author(s)Jeffrey A. Loeb, MD, PhD
Dr. Loeb summarizes a global and one-of-a-kind approach of biomarker and drug discovery using systems biology of human brain tissues.
Advertisement
Advertisement
Related to this article
Here's some of what is coming soon to NeurologyLive® this week.
Newly presented post hoc analyses examined diazepam nasal spray for status epilepticus in seizure clusters and intervals between clusters in children, alongside real-world data on rescue medication prescribing.
A retrospective 10-center U.S. study found stiripentol reduced convulsive seizure frequency, status epilepticus episodes, and emergency health care use in patients with Dravet syndrome.
A phase 1b/2 trial is testing an intrathecal antisense oligonucleotide designed to lower KCNT1 expression in children with a severe, drug-resistant epilepsy syndrome.
Here's some of what is coming soon to NeurologyLive® this week.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Remibrutinib Lowers Relapse Rate vs Teriflunomide in Relapsing MS
2
FDA Accepts Troriluzole NDA Resubmission for Spinocerebellar Ataxia
3
Tenecteplase Benefit Before Thrombectomy Varies by Stroke Cause, Study Shows
4
Phase 2 ACUITY Analysis Shows Privosegtor Associated With Smaller Early NfL and GFAP Increases in Acute Optic Neuritis
5